SEQUENCE LISTING





<110> APPLICANT: Bayer Schering Pharma Aktiengesellschaft
<120> TITLE OF INVENTION: Stabilized radiopharmaceutical composition
<141> CURRENT FILING DATE:  
<160> NUMBER OF SEQ ID NO.S: 2
<170> SOFTWARE: PatentIn Ver. 3.3

<210> SEQ ID NO. 1
<211> LENGTH: 357
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: antibody or
      antibody fragment
<220> FEATURE: 
<223> OTHER INFORMATION: L19 SIP homodimer, sequence monomer 1
<400> SEQUENCE: 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 
1			5			 10			    15
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ser Met 
	   20			     25		       30
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile 
35			   40			     45			  50
Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 
		 55			   60			      65
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser 
     70			 75			   80				85
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Phe Pro Tyr 
		     90			 95			   100
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Asp Gly 
	  105		          110			 115
Ser Ser Gly Gly Ser Gly Gly Ala Ser Glu Ile Val Leu Thr Gln Ser Pro 
120			  125			     130			 135
Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala 
		140			   145	           150
Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly 
    155			160		         165		     170
Gln Ala Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Ser Arg Ala Thr Gly Ile 
		    175			 180			   185
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
        190	         	    195			 200		     
Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Gly 
205		        210			     215			 220
Arg Ile Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly 
            225			  230			     235		     
Gly Ser Gly Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro 
    240		      245			   250		     255
Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn 
	          260			 265			   270
Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu 
        275		          280			 285			 
Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly 
290		        295			     300		       305
Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys 
            310			  315			     320		     
Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr 
    325		      330			   335		     340
Val Gln Arg Ala Val Ser Val Asn Pro Glu Ser Ser Arg Arg Gly Gly Cys
	          345			 350		         355



<210> SEQ ID NO. 2
<211> LENGTH: 357
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: antibody or
      antibody fragment
<220> FEATURE: 
<223> OTHER INFORMATION: L19 SIP homodimer, sequence monomer 2
<400> SEQUENCE: 2
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 
1			5			 10			    15
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ser Met 
	   20			     25		       30
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile 
35			   40			     45			  50
Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 
		 55			   60			      65
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser 
     70			 75			   80				85
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Phe Pro Tyr 
		     90			 95			   100
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Asp Gly 
	  105		          110			 115
Ser Ser Gly Gly Ser Gly Gly Ala Ser Glu Ile Val Leu Thr Gln Ser Pro 
120			  125			     130			 135
Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala 
		140			   145	           150
Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly 
    155			160		         165		     170
Gln Ala Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Ser Arg Ala Thr Gly Ile 
		    175			 180			   185
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
        190	         	    195			 200		     
Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Gly 
205		        210			     215			 220
Arg Ile Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly 
            225			  230			     235		     
Gly Ser Gly Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro 
    240		      245			   250		     255
Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn 
	          260			 265			   270
Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu 
        275		          280			 285			 
Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly 
290		        295			     300		       305
Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys 
            310			  315			     320		     
Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr 
    325		      330			   335		     340
Val Gln Arg Ala Val Ser Val Asn Pro Glu Ser Ser Arg Arg Gly Gly Cys
	          345			 350		         355

